Axim Biotechnologies is an early-stage medical diagnostics company focused on point-of-care testing for Dry Eye Disease. Axim's core products are two FDA-cleared rapid lateral flow assay tests that use a small sample of a patient's tear fluid to measure biomarkers — Lactoferrin (a marker for aqueous-deficient dry eye) and IgE (a marker for ocular allergies). The tests take under 10 minutes and produce quantitative results, which Axim argues is a clinical advantage over competitors that offer only binary positive/negative output. Axim also supplies a portable digital reader, the iPeak, sourced from IUL, that reads the test strips. Axim sells exclusively through Verséa Ophthalmics, its global distribution partner, which in turn sells to eye care clinics. Axim follows a razor/razor-blade model: readers are sold at approximately cost to build the installed base, while recurring revenue comes from single-use disposable test cassettes consumed with each patient test. The tests are reimbursed by Medicare and private insurance, and Axim prices test kits at roughly half the CMS reimbursement rate, giving physicians a roughly 2:1 return on supply cost. A key constraint is that Axim's tests carry CLIA Moderate Complexity certification, requiring clinics to hold compliance certificates — a barrier that limits market penetration relative to CLIA-waived competitors. Axim is pursuing a CLIA waiver and has a third test for MMP-9 pending FDA clearance. Axim is pre-profitability, with an accumulated deficit of approximately $72M and going concern doubts raised by its auditors.